Amdocs Limited $DOX Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp decreased its position in Amdocs Limited (NASDAQ:DOX) by 2.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 642,565 shares of the technology company’s stock after selling 16,462 shares during the period. Boston Trust Walden Corp’s holdings in Amdocs were worth $41,934,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Scotia Capital Inc. raised its holdings in shares of Amdocs by 3.5% during the third quarter. Scotia Capital Inc. now owns 4,289 shares of the technology company’s stock valued at $352,000 after buying an additional 145 shares during the last quarter. WealthCollab LLC raised its stake in Amdocs by 94.5% during the 3rd quarter. WealthCollab LLC now owns 356 shares of the technology company’s stock valued at $29,000 after acquiring an additional 173 shares in the last quarter. Blair William & Co. IL raised its stake in Amdocs by 5.5% during the 3rd quarter. Blair William & Co. IL now owns 3,393 shares of the technology company’s stock valued at $278,000 after acquiring an additional 177 shares in the last quarter. Two Point Capital Management Inc. boosted its position in Amdocs by 0.7% during the 4th quarter. Two Point Capital Management Inc. now owns 28,978 shares of the technology company’s stock worth $2,333,000 after acquiring an additional 191 shares during the period. Finally, Mercer Global Advisors Inc. ADV boosted its position in Amdocs by 2.2% during the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 9,634 shares of the technology company’s stock worth $790,000 after acquiring an additional 204 shares during the period. Institutional investors and hedge funds own 92.02% of the company’s stock.

Amdocs Stock Performance

Shares of NASDAQ DOX opened at $51.75 on Friday. Amdocs Limited has a 1 year low of $49.79 and a 1 year high of $93.44. The firm has a market cap of $5.59 billion, a P/E ratio of 10.35, a PEG ratio of 0.89 and a beta of 0.41. The stock has a fifty day moving average price of $59.39 and a two-hundred day moving average price of $68.30. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.98 and a current ratio of 0.98.

Amdocs (NASDAQ:DOX) last posted its quarterly earnings data on Thursday, May 14th. The technology company reported $1.78 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.01. Amdocs had a return on equity of 19.77% and a net margin of 11.81%.The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the business earned $1.78 EPS. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. Research analysts forecast that Amdocs Limited will post 6.56 EPS for the current fiscal year.

Amdocs Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.569 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $2.28 annualized dividend and a yield of 4.4%. Amdocs’s payout ratio is 45.60%.

More Amdocs News

Here are the key news stories impacting Amdocs this week:

• Neutral Sentiment: KeyCorp reiterated a “Sector Weight” rating on Amdocs and published quarterly earnings estimates that are mostly in line with current expectations, including FY2026 EPS of $6.54 versus consensus of $6.56.
• Neutral Sentiment: The firm’s FY2027 EPS estimate of $7.02 suggests modest expected earnings growth, which may help support sentiment, but the update does not appear materially more bullish than the market already expected.
• Neutral Sentiment: Additional posts referenced Amdocs in broad “cheap stocks” and short-interest content, but those items do not appear to include new company-specific fundamentals likely driving the stock today. Article Title

Analyst Ratings Changes

A number of research analysts have recently commented on DOX shares. KeyCorp started coverage on Amdocs in a report on Monday. They set a “sector weight” rating on the stock. Cfra downgraded shares of Amdocs to a “sell” rating in a report on Thursday, May 14th. Stifel Nicolaus decreased their target price on shares of Amdocs from $88.00 to $71.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. Wall Street Zen raised shares of Amdocs from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Amdocs in a research report on Friday, May 8th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $86.67.

About Amdocs

Amdocs (NASDAQ: DOX) is a global software and services provider specializing in solutions for communications, media and entertainment companies. The company designs, develops and integrates revenue management, customer experience and digital services platforms that enable service providers to launch and monetize new offerings, streamline operations and enhance subscriber engagement. Amdocs’ product suite encompasses billing and order management, customer relationship management, digital commerce and network function virtualization, supported by professional services for implementation, integration and managed operations.

Founded in 1982 and structured as a separate public company in 1998, Amdocs has its corporate headquarters in Chesterfield, Missouri, and maintains major development centers in Ra’anana, Israel.